Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance

PHIBRO ANIMAL HEALTH CORP

2024-Q2 EPS reported -$0.17 revenue$481,292,000

Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.
GAAP net income $1.3M, diluted EPS $0.03, down from $7.2M and $0.18 a year ago.
Adjusted EBITDA $29.5M (-5% YoY); adjusted diluted EPS $0.33 (-2%).
FY2024 guidance: reaffirmed adjusted EBITDA $106-$112M; GAAP net income lowered to $12-$17M (down 55%).
Includes $4.2M Brazil employment tax litigation charge and $7.5M foreign currency losses from Argentina devaluation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended December 31, 2023 results: revenue $249.9 million, net income $1.3 million, EPS $0.03. Guidance reaffirmed.

Period: the fiscal quarter ended December 31, 2023
Revenue: $249.9 million
Net income: $1.3 million
EPS: $0.03
Guidance: reaffirmed
Result: reported results

Exact text from the filing

guidance for the year ending June 30, 2024. Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) - Net sales of $249.9 million, an increase of $5.3 million, or 2% - Net income of $1.3 million, a decrease of $5.9 million - Diluted earnings per share of $0.03, a decrease of $0.15 - Adjusted EBITDA of $29.5

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001558370-24-000864

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.